Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. (Q44727002)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. |
scientific article |
Statements
1 reference
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. (English)
1 reference
Jacek Jassem
1 reference
Tadeusz Pienkowski
1 reference
Anna Pluzanska
1 reference
Maurizio Voi
1 reference
Leonard Reyno
1 reference
Lesley Seymour
1 reference
Dongsheng Tu
1 reference
Susan Dent
1 reference
Karen Gelmon
1 reference
Barbara Walley
1 reference
Vera Gorbunova
1 reference
Avgust Garin
1 reference
Janet Dancey
1 reference
Laura Pearce
1 reference
Mary MacNeil
1 reference
Susan Marlin
1 reference
David Lebwohl
1 reference
Kathleen Pritchard
1 reference
National Cancer Institute of Canada Clinical Trials Group Study MA.19
1 reference
1 January 2004
1 reference
1 reference
Identifiers
1 reference